Skip to main content

Table 3 Adjusted multivariate model of all-cause mortality

From: Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model

 

HR

95% CI

P-value

Smoking, ever (vs. never)a

0.97

0.25–3.63

0.9640

C-reactive protein, per 1 mg/dLa

0.99

0.93–1.04

0.5770

Rheumatoid factor, per 10 U/mL increasea

5.93

0.65–50.56

0.1110

ACPA, positive (vs. negative)b, c

0.29

0.07–1.53

0.1329

KL-6, per 100 U/mL increasea

0.99

0.94–1.02

0.4416

UIP pattern on HRCT (vs. other patterns)b

1.84

0.99–3.56

0.0548

Infection-triggered AEd

3.16

0.87–9.28

0.0760

Treatment for RA before AE, yes (vs. no)

 Prednisolone ≤ 7.5 mg/day

6.78

0.47–111.3

0.1595

 Methotrexate

1.16

0.38–3.18

0.7806

 Tacrolimus

0.83

0.27–2.28

0.7224

 Bucillamine

1.81

0.64–4.51

0.2468

 Salazosulfapyridine

0.69

0.23–1.78

0.4491

Treatment for AE (vs. CS monotherapy)

 CS + IS

1.13

0.47–2.81

0.7858

 CS + IVCY

1.67

0.62–4.56

0.3108

 CS + CNI

0.91

0.28–2.77

0.8741

  1. Adjusted for age, sex, baseline %FVC, and PaO2/FiO2 ratio
  2. ACPA anti-cyclic citrullinated peptide antibody, KL-6 Krebs von den Lungen-6, UIP usual interstitial pneumonia, HRCT high-resolution computed tomography, RA rheumatoid arthritis, AE acute exacerbation, CS corticosteroids, IS immunosuppressant, IVCY intravenous cyclophosphamide, CNI calcineurin inhibitor, HR hazard ratio, CI confidence interval
  3. aAt AE onset
  4. bWithin 12 months before AE
  5. cn = 46
  6. dDue to an apparent infection with an identifiable cause that occurred within 1 month before AE onset